Fresenius Kabi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FRESENIUS KABI, and when can generic versions of FRESENIUS KABI drugs launch?
FRESENIUS KABI has three hundred and seven approved drugs.
There are twenty-three US patents protecting FRESENIUS KABI drugs. There are two tentative approvals on FRESENIUS KABI drugs.
There are one hundred and twenty-nine patent family members on FRESENIUS KABI drugs in twenty-five countries and four hundred and sixty-two supplementary protection certificates in seventeen countries.
Summary for Fresenius Kabi
International Patents: | 129 |
US Patents: | 23 |
Tradenames: | 248 |
Ingredients: | 185 |
NDAs: | 307 |
Patent Litigation for Fresenius Kabi: | See patent lawsuits for Fresenius Kabi |
PTAB Cases with Fresenius Kabi as petitioner: | See PTAB cases with Fresenius Kabi as petitioner |
PTAB Cases with Fresenius Kabi as patent owner: | See PTAB cases with Fresenius Kabi as patent owner |
Drugs and US Patents for Fresenius Kabi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | ACETYLCYSTEINE | acetylcysteine | INJECTABLE;INTRAVENOUS | 200644-001 | Nov 7, 2012 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi | PIPERACILLIN AND TAZOBACTAM | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 203719-003 | May 18, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | VINORELBINE TARTRATE | vinorelbine tartrate | INJECTABLE;INJECTION | 076849-001 | Apr 18, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Fresenius Kabi Usa | ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 077897-002 | Nov 27, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi | LACTULOSE | lactulose | SOLUTION;ORAL | 090503-001 | Jan 25, 2012 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | MORPHINE SULFATE | morphine sulfate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 204223-001 | Oct 30, 2013 | RX | Yes | Yes | 9,192,608 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | LEVOTHYROXINE SODIUM | levothyroxine sodium | POWDER;INTRAVENOUS | 202231-003 | Jun 24, 2011 | AP | RX | Yes | Yes | 9,168,238 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Kabi
Paragraph IV (Patent) Challenges for FRESENIUS KABI drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | Oral Solution | 5 mg/5mL | ➤ Subscribe | 2011-02-25 |
➤ Subscribe | Tablets | 2 mg, 4 mg, and 8 mg | ➤ Subscribe | 2013-08-05 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Injection | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | ➤ Subscribe | 2006-11-13 |
➤ Subscribe | Injection | 2 mg/mL, 200 mL | ➤ Subscribe | 2015-09-03 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
➤ Subscribe | Injection | 2 mg/mL | ➤ Subscribe | 2011-06-22 |
➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2011-11-04 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL | ➤ Subscribe | 2015-01-30 |
International Patents for Fresenius Kabi Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2011201893 | ⤷ Try a Trial |
Brazil | PI0415438 | ⤷ Try a Trial |
Spain | 2695158 | ⤷ Try a Trial |
European Patent Office | 2421522 | ⤷ Try a Trial |
Brazil | PI0408780 | ⤷ Try a Trial |
South Africa | 200409019 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2013033194 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Kabi Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2435024 | 2021C/518 | Belgium | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210 |
1020461 | C300482 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105 |
2785706 | LUC00158 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318 |
0836511 | SPC/GB06/022 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 |
2701720 | 23C1000 | France | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
2465580 | SPC/GB21/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
0268956 | 1999C0030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.